Recent 8-K filings for TBPH

• May 7, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Theravance Q1 net loss narrows to $4.9M; YUPELRI revenue up 15%; all generic litigation settled

  YUPELRI collaboration revenue of $17.7M, up 15% YoY; implied 35% share of net sales $21.9M (+7%).

• March 30, 2026, 7:59 PM ET litigation materiality 0.70 positive item 8.01

  Theravance settles YUPELRI patent suit; generic license start April 23, 2039

  Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.

• March 19, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing

  Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.

• March 3, 2026, 6:59 PM ET other material materiality 0.85 negative item 2.02item 2.05item 7.01item 9.01 ◈ Restructurings & Charges

  Theravance Biopharma Phase 3 CYPRESS study fails; plans 50% workforce cut and strategic review

  Phase 3 CYPRESS study of ampreloxetine for nOH in MSA did not meet primary endpoint (OHSA composite); program halted.

• November 10, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Theravance Biopharma Q3 2025: YUPELRI net sales hit all-time high $71.4M, achieves non-GAAP breakeven

  YUPELRI net sales all-time high $71.4M (15% YoY); Viatris collaboration revenue $20M (+19%).

• August 25, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Theravance Biopharma completes Phase 3 enrollment for ampreloxetine in nOH due to MSA; topline Q1 2026

  Enrollment completed in open-label portion of pivotal Phase 3 CYPRESS study (NCT05696717) for nOH due to MSA.

• August 20, 2025, 7:59 PM ET other material materiality 0.70 positive item 8.01

  Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039

  Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.

• August 12, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%

  YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.

• June 26, 2025, 7:59 PM ET regulatory materiality 0.60 positive item 8.01item 9.01

  Theravance Biopharma's YUPELRI approved by China's NMPA; $7.5M milestone triggered

  China's NMPA approved YUPELRI (revefenacin) as first once-daily nebulized LAMA for COPD maintenance.

• June 6, 2025, 7:59 PM ET litigation materiality 0.70 neutral item 8.01

  Theravance settles YUPELRI patent litigation with Eugia; generic launch set for 2039

  Settlement resolves Hatch-Waxman litigation over YUPELRI (revefenacin) with Eugia (Aurobindo).

• June 2, 2025, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M

  Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.

• May 8, 2025, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Theravance Biopharma Q1 net loss $13.6M; YUPELRI sales up 6% to $58.3M

  YUPELRI net sales of $58.3M recognized by Viatris, up 6% vs Q1 2024; Theravance's implied 35% share $20.4M.

• February 26, 2025, 6:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  Theravance Biopharma reports record Q4 and full year 2024 financial results with YUPELRI and TRELEGY milestones

  YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.

• November 12, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Theravance Biopharma Q3 2024: YUPELRI sales record $62.2M (+7%); net loss widens; board forms strategic review

  Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).

• September 23, 2024, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039

  Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.

• August 5, 2024, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Theravance Biopharma Q2 net loss $16.5M; YUPELRI net sales down 1%; CYPRESS enrollment delayed

  Q2 2024 net loss of $16.5M vs $15.6M YoY; non-GAAP net loss from operations $6.3M.

• May 13, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M

  Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.

• February 28, 2024, 6:59 PM ET litigation materiality 0.70 positive item 8.01

  Theravance settles YUPELRI patent litigation with Lupin; generic launch delayed to April 23, 2039

  Settlement grants Lupin a royalty-free, non-exclusive license to market generic revefenacin starting April 23, 2039.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.70 · Most common event earnings

11 positive 5 negative 7 neutral

source · TBPH on sec.gov